coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.yohimbeyohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.ziprasidonealfuzosin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Monitor Closely (240)acebutololalfuzosin and acebutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.aceclofenacaceclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.acemetacinacemetacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.aldesleukinaldesleukin increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.amifostineamifostine, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.amitriptylineamitriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and amitriptyline both increase QTc interval. Use Caution/Monitor.amlodipinealfuzosin and amlodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.apomorphineapomorphine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and apomorphine both decrease QTc interval. Use Caution/Monitor.arformoterolarformoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and arformoterol both increase QTc interval. Use Caution/Monitor.aripiprazolearipiprazole and alfuzosin both increase QTc interval. Use Caution/Monitor.artemetherartemether and alfuzosin both increase QTc interval. Use Caution/Monitor.asenapinealfuzosin and asenapine both increase anti-hypertensive channel blocking. Use Caution/Monitor.aspirinaspirin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.aspirin rectalaspirin rectal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.aspirin/citric acid/sodium bicarbonateaspirin/citric acid/sodium bicarbonate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.atenololalfuzosin and atenolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.atomoxetineatomoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.avanafilavanafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.azithromycinazithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor.bedaquilinealfuzosin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closelybelzutifanbelzutifan will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. benazeprilbenazepril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.alfuzosin increases effects of benazepril by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension.betaxololalfuzosin and betaxolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.bisoprololalfuzosin and bisoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.buprenorphine buccalbuprenorphine buccal and alfuzosin both increase QTc interval. Use Caution/Monitor.buprenorphine subdermal implantbuprenorphine subdermal implant and alfuzosin both increase QTc interval. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and alfuzosin both increase QTc interval. Use Caution/Monitor.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and alfuzosin both increase QTc interval. Use Caution/Monitor.captoprilcaptopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.alfuzosin increases effects of captopril by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood pressure. Monitor blood pressure.carbamazepinecarbamazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.carbidopacarbidopa increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Monitor for hypotension.carvedilolalfuzosin and carvedilol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.celecoxibcelecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.celiprololalfuzosin and celiprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.cenobamatecenobamate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.chlorpromazinechlorpromazine and alfuzosin both increase QTc interval. Use Caution/Monitor.choline magnesium trisalicylatecholine magnesium trisalicylate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.cimetidinecimetidine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ciprofloxacinciprofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and ciprofloxacin both increase QTc interval. Use Caution/Monitor.citalopramcitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.clarithromycinclarithromycin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clarithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor.clevidipinealfuzosin and clevidipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.clomipramineclomipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.clozapineclozapine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and clozapine both increase QTc interval. Use Caution/Monitor.crizotinibcrizotinib increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.crizotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.crofelemercrofelemer increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.dabrafenibdabrafenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dasatinibdasatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and dasatinib both increase QTc interval. Use Caution/Monitor.deferasiroxdeferasirox will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.degarelixdegarelix and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and degarelix both decrease QTc interval. Use Caution/Monitor.delafloxacindelafloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.desipraminedesipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and desipramine both increase QTc interval. Use Caution/Monitor.deutetrabenazinealfuzosin and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).diclofenacdiclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diflunisaldiflunisal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diltiazemdiltiazem will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased exposure to alfuzosin may be expected when alfuzosin is concomitantly used with diltiazem. Monitor pulse and blood pressure.dofetilidedofetilide and alfuzosin both increase QTc interval. Use Caution/Monitor.dolasetrondolasetron and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and dolasetron both increase QTc interval. Use Caution/Monitor.donepezildonepezil and alfuzosin both increase QTc interval. Use Caution/Monitor.doxazosinalfuzosin and doxazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.doxepindoxepin and alfuzosin both increase QTc interval. Use Caution/Monitor.droperidoldroperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.duvelisibduvelisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.efavirenzefavirenz and alfuzosin both increase QTc interval. Use Caution/Monitor.elagolixelagolix will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.eliglustatalfuzosin and eliglustat both increase QTc interval. Use Caution/Monitor.enalaprilenalapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.encorafenibencorafenib, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.encorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.eribulineribulin and alfuzosin both increase QTc interval. Use Caution/Monitor.erythromycin baseerythromycin base will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin base and alfuzosin both increase QTc interval. Use Caution/Monitor.erythromycin ethylsuccinateerythromycin ethylsuccinate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin ethylsuccinate and alfuzosin both increase QTc interval. Use Caution/Monitor.erythromycin lactobionateerythromycin lactobionate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin lactobionate and alfuzosin both increase QTc interval. Use Caution/Monitor.erythromycin stearateerythromycin stearate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.erythromycin stearate and alfuzosin both increase QTc interval. Use Caution/Monitor.escitalopramescitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and escitalopram both increase QTc interval. Use Caution/Monitor.esmololalfuzosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.etodolacetodolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fedratinibfedratinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.felodipinealfuzosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.fenoprofenfenoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fingolimodfingolimod and alfuzosin both increase QTc interval. Use Caution/Monitor.fluoxetinealfuzosin and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.fluphenazinefluphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and fluphenazine both increase QTc interval. Use Caution/Monitor.flurbiprofenflurbiprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fluvoxaminefluvoxamine and alfuzosin both increase QTc interval. Use Caution/Monitor.formoterolformoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and formoterol both increase QTc interval. Use Caution/Monitor.foscarnetfoscarnet and alfuzosin both increase QTc interval. Use Caution/Monitor.fosinoprilfosinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.fostemsaviralfuzosin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir. gemifloxacingemifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and gemifloxacin both increase QTc interval. Use Caution/Monitor.gemtuzumabalfuzosin and gemtuzumab both increase QTc interval. Use Caution/Monitor.gilteritinibalfuzosin and gilteritinib both increase QTc interval. Use Caution/Monitor.goserelingoserelin and alfuzosin both increase QTc interval. Use Caution/Monitor.granisetronalfuzosin and granisetron both increase QTc interval. Use Caution/Monitor.haloperidolhaloperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and haloperidol both increase QTc interval. Use Caution/Monitor.histrelinhistrelin and alfuzosin both increase QTc interval. Use Caution/Monitor.hydroxyzinealfuzosin and hydroxyzine both increase QTc interval. Use Caution/Monitor.ibuprofenibuprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ibuprofen IVibuprofen IV decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.iloperidoneiloperidone increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor.iloperidone increases effects of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.imidaprilimidapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.indacaterol, inhaledindacaterol, inhaled and alfuzosin both increase QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.alfuzosin and indacaterol, inhaled both increase QTc interval. Use Caution/Monitor.indapamideindapamide and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and indapamide both increase QTc interval. Use Caution/Monitor.indomethacinindomethacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.isradipinealfuzosin and isradipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.isradipine and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and isradipine both increase QTc interval. Use Caution/Monitor.istradefyllineistradefylline will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.ketoconazoleketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ketoprofenketoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolacketorolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolac intranasalketorolac intranasal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.labetalolalfuzosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.lapatiniblapatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and lapatinib both increase QTc interval. Use Caution/Monitor.lenacapavirlenacapavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.lenvatinibalfuzosin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.letermovirletermovir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.leuprolideleuprolide and alfuzosin both increase QTc interval. Use Caution/Monitor. Increases risk of torsades de pointeslevalbuterolalfuzosin and levalbuterol both increase QTc interval. Use Caution/Monitor.levofloxacinlevofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.alfuzosin and levofloxacin both increase QTc interval. Use Caution/Monitor.levoketoconazolelevoketoconazole will increase the level or effect